A radioimmunoassay (RIA) for human a-fetoprotein (a-FP) was developed. The sensitivity threshold of the method is 250 picograms per ml, which means that it is 20,000 Immunological demonstration of a-fetoprotein is widely used in the diagnosis of primary liver cancer (PLC) and malignant embryonal teratoma. Abelev et al. (1963) were the first to show the association of a fetal protein with cancer in mice. In humans, Tatarinov (1965) demonstrated the presence in PLC of a protein which was immunoelectrophoretically indistinguishable from a-FP. This finding has been confirmed and extended by several authors (Abelev et al., 1967;Abelev, 1968;Masopust et al., 1968;Foli et al., 1969;Purves et al., 1970).The method used to demonstrate a-FP in hepatoma sera has generally been immunodiffusion in gel or its more sensitive modifications.Received: July 30, 1971.
374Some patients with histologically verified PLC have no detectable a-FP in their sera when tested by immunodiffusion or electroimmunodiffusion (Masopust et al., 1968;Foli et al., 1969;Purves et al., 1970). This raises the question of whether these sera are truly negative or would show elevated a-FP concentrations if analyzed by a more sensitive technique.Recent work (Purves and Bersohn, 1969;Abelev et al., 1971)shows that more a-FP-positive PLC cases are found if the sensitivity of the technique for demonstrating a-FP is increased. Using radioautography of the a-FP immunoprecipitate and aggregate-hemagglutination, Abelev et al. (1971) were also able to find a-FP in the sera of